Mabvax Therapeutics Holdings Inc Stock Nasdaq
Equities
US87959M2089
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
Sales 2016 | 148K 203K | Sales 2017 | - | Capitalization | 14.41M 19.81M |
---|---|---|---|---|---|
Net income 2016 | -17M -23.36M | Net income 2017 | -19M -26.11M | EV / Sales 2016 | 147 x |
Net Debt 2016 | 470K 646K | Net Debt 2017 | 2.48M 3.41M | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 14-07-07 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 14-07-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 14-07-07 |
1st Jan change | Capi. | |
---|---|---|
+15.82% | 121B | |
+20.35% | 113B | |
+17.47% | 26.02B | |
-25.31% | 19.39B | |
-19.51% | 15.91B | |
-19.67% | 15.09B | |
-46.87% | 15.06B | |
+62.55% | 14.93B | |
+6.34% | 13.85B |